



Alpa Laboratories Ltd.

33/2, Pigdamber A.B. Road - 453 446 Distt. Indore - (M.P.) India

Phone No. : +91-731- 429 4567 Fax No. : +91-731- 429 4444

Email : mail@alpalabs.in

CIN : L85195MP1988PLC004446

29th June, 2020

To,
Listing Department,
BSE Limited.
Rotunda Building, P J Towers
Dalal Street, Fort,
Mumbai – 400 001

To,
Listing Department,
National Stock Exchange of India Limited.
Exchange Plaza', C-1, Block G,
Bandra - Kurla Complex,
Bandra (E), Mumbai – 400 051

Subject: Audited Financial Results for the year ended 31st March,2020

Reference: Scrip Code: ALPA ; ISIN: INE385I01010

Dear Sir

Please refer to our letter dated 22nd June,2020

Pursuant to the applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find the following.

1. Approved and taken on record the Audited Financial Results (Standalone & Consolidated) along with Auditor's Report by the statutory auditors of the company thereon, for the quarter and year ended on 31st March, 2020 and declaration in respect of the Audit reports with unmodified opinion.

2. Auditors Report for audited financial statements for both standalone and consolidated for the year ended 31st March,2020


Further in accordance with SEBI Circular dated 12th May 2020 read with circular dated 26th March,2020 granting relaxations from the provisions of Regulation 47 pf the SEBI Listing Regulations, the above financial results will not be published in the newspaper

The Audited Financial Results and the Audit Report along with the declaration as aforesaid on results for the quarter/ year ended 31st March,2020 are enclosed herewith.

You are requested to take the same on records pursuant to Regulations 30 of SEBI LODR,2015.

You are requested to take the same on records.

For ALPA LABORATORIES LIMITED


Megha Neema
Company Secretary



ALPA LABORATORIES LIMITED

Financial Results for Quarter and Financial Year ended 31st March 2020

33/2 PIGDAMBER, A.B. ROAD, RAU

INDORE (M.P.) 453446

(Rs. in lacs except EPS)

I. Statement of Profit and Loss - Standalone					
Particulars	Standalone Results				
	Quarter Ended			Year Ended	
	Mar-20	Dec-19	Mar-19	Mar-20	Mar-19
	Audited	Unaudited	Unaudited	Audited	Audited
1. Income					
a) Revenue from operations	1,816.28	2,412.64	1,909.42	8,596.91	7,798.80
b) Other Income	76.99	116.41	238.05	296.67	506.52
Total income from operations	1,893.27	2,529.05	2,147.47	8,893.58	8,305.32
2. Expenses					
a) Cost of materials consumed	901.75	1,230.82	1,130.96	4,948.01	4,645.84
b) Purchases of stock-in-trade	78.67	20.75	26.26	193.83	84.66
c) Changes in inventories of finished products, work in progress and stock in trade	(124.93)	184.32	171.56	(42.41)	152.61
d) Employee benefit expenses	329.13	292.28	382.55	1,182.43	1,204.10
e) Finance costs	3.69	2.81	6.90	19.94	56.87
f) Depreciation and amortization expense	33.16	28.68	24.31	114.20	109.57
g) Other expenses					
Manufacturing & Operating	106.92	105.04	111.43	427.09	425.80
Others	641.64	355.29	391.58	1,542.76	1,163.65
Total expenses	1,970.02	2,219.99	2,245.55	8,385.85	7,843.09
3. Profit/(Loss) before exceptional items and tax (1-2)	(76.75)	309.06	(98.08)	507.73	462.23
4. Exceptional Items	-	-	-	-	-
5. Profit/ Loss(-) before tax (3+/-4)	(76.75)	309.06	(98.08)	507.73	462.23
6. Tax (Expenses)/ Benefit					
Current tax	(190.00)	-	(125.00)	(190.00)	(125.00)
Deffered Tax	75.48	-	(59.02)	75.48	(59.02)
Tax Related to Earlier Years	14.60	-	18.72	14.60	16.71
7. Profit/ Loss(-) for the period (5-/+6)	(176.67)	309.06	(263.38)	407.81	294.92
8. Other Comprehensive Income					
(i) (a) Items that will not be reclassified to profit or loss	0.31	0.50	(6.73)	2.49	(6.60)
(b) Tax expense/(benefit) on items that will not be reclassified to profit or loss	-	-	-	-	-
(ii) (a) Items that will be reclassified to profit & loss	-	-	-	-	-
(b) Tax expense/(benefit) on items that will be reclassified to profit or loss	-	-	-	-	-
Total Other comprehensive (loss)/ income (net of tax)	0.31	0.50	(6.73)	2.49	(6.60)
9. Total comprehensive income for the period	(176.35)	309.57	(270.11)	410.30	288.32
10. Paid-up equity share capital (Face Value Rs. 10 Each)	2,104.06	2,104.06	2,104.06	2,104.06	2,104.06
11. Other equity (excluding revaluation reserve)				8,918.90	8,508.60
12. Debenture Redemption Reserve					
13. Basic and Diluted Earnings per share after extraordinary items (not annualized)	(0.84)	1.47	(1.28)	1.95	1.37

For Alpa Laboratories Ltd.

Mahendra
 Mahendra Singh Chawla
 Director
 DIN-00362058



INDEPENDENT AUDITORS REPORT ON AUDIT OF ANNUAL STANDALONE FINANCIAL RESULTS AND REVIEW OF THE QUARTERLY FINANCIAL RESULTS.

TO THE BOARD OF DIRECTORS OF

ALPA LABORATORIES LIMITED

OPINION

I have (a) audited the standalone financial statements of the year ended 31st March, 2020 and (b) reviewed the standalone financial results for the quarter ended 31st March 2020 which were subject to limited review by us both included in the accompanying "Statement of Financial results for the quarter and year ended 31st March 2020 of **ALPA LABORATORIES LIMITED, being submitted by the company pursuant to the requirements of regulation 33 of the SEBI LODR, 2015 as amended**

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements.

a. are presented in accordance with the requirements of the regulation 33 of the Listing Regulation in this regard.


b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian accounting standards and other accounting principle generally accepted in India of the net profit and other comprehensive income and other financial information for the year ended 31st March, 2020

Basis for opinion

I conducted our audit in accordance with the Standards on Auditing (SAs) specified U/s. 143(10) of the Companies Act, 2013 ("The Act"). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. / We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the financial statements.

Management and Board of Directors Responsibilities for the standalone audited financial results

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these standalone financial statements that give a true and fair view of the net profit and other comprehensive income and other financial information in





accordance with the accounting principles generally accepted in India, including the Accounting Standards specified u/s 133 of the Act and other accounting principles generally accepted in India and in compliance with regulation 33 of the listing regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the company's financial reporting process.


Auditor's Responsibility for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

• Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. U/s.143(3)(i) of the 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls



Anuradha Ratnaparkhi & Associates

CHARTERED ACCOUNTANTS

Anuradha Ratnaparkhi

M.com., FCA



9D, Sampat Farms, Survey No. 15/26,
Opp. Agrawal Public School,
Bicholi Mardana Road, Indore 452 016 (M.P.)
Tel. : +91 731-4979244, M : +91 98934-62644
E-mail : associate@caanuradha.co.in

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

OTHER MATTERS.

The statement includes the results for the quarter ended 31st March 2020 being the balancing figure between audited figures in respect of the full financial year and the published year ton date figure upto the third quarter of the current financial year which were subject to limited review by us.

For Anuradha Ratnaparkhi & Associates.

Chartered Accountants

Firm-Registration No.023451C

Anuradha Ratnaparkhi

Proprietor

Membership Number:075412

UDIN- 20075412AAAAAC2728



Place: Indore

Date: June 29,2020

ALPA LABORATORIES LIMITED

Financial Results for Quarter and Financial Year ended 31st March 2020

33/2 PIGDAMBER, A.B. ROAD, RAU
INDORE (M.P.) 453446
(Rs. in lacs except EPS)

II. Statement of Profit and Loss - Consolidated					
Particulars	Consolidated Results				
	Quarter Ended			Year Ended	
	Mar-20	Dec-19	Mar-19	Mar-20	Mar-19
	Audited	Unaudited	Unaudited	Audited	Audited
1. Income					
a) Revenue from operations	1,816.28	2,412.64	1,909.41	8,596.91	7,798.80
b) Other Income	77.90	116.04	240.43	291.24	529.88
Total income from operations	1,894.18	2,528.68	2,149.84	8,888.15	8,328.68
2. Expenses					
a) Cost of materials consumed	901.75	1,230.82	1,130.96	4,948.01	4,645.84
b) Purchases of stock-in-trade	78.67	20.75	26.26	193.83	84.66
c) Changes in inventories of finished products, work in progress and stock in trade	(124.93)	184.32	171.56	(42.41)	152.61
d) Employee benefit expenses	329.13	292.28	382.54	1,182.43	1,204.10
e) Finance costs	3.36	2.81	6.90	19.62	56.87
f) Depreciation and amortization expense	83.73	79.24	74.87	316.45	311.82
g) Other expenses					
Manufacturing & Operating	106.92	105.04	111.38	427.09	425.80
Others	642.67	355.45	377.31	1,552.38	1,171.35
Total expenses	2,021.29	2,270.71	2,281.78	8,597.40	8,053.05
3. Profit/(Loss) before exceptional items and tax (1-2)	(127.11)	257.97	(131.94)	290.75	275.63
4. Exceptional Items	-	-	-	-	-
5. Profit/ Loss(-) before tax (3+/-4)	(127.11)	257.97	(131.94)	290.75	275.63
6. Tax (Expenses)/ Benefit					
Current tax	(190.00)	-	(125.00)	(190.00)	(125.00)
Deffered Tax	75.48	-	(59.02)	75.48	(59.02)
Tax Related to Earlier Years	9.11	-	15.17	9.11	9.56
7. Profit/ Loss(-) for the period (5-/+6)	(232.52)	257.97	(300.79)	185.34	101.16
8. Other Comprehensive Income					
(i) (a) Items that will not be reclassified to profit or loss	0.31	0.50	(6.73)	2.49	(6.60)
(b) Tax expense/(benefit) on items that will not be reclassified to profit or loss	-	-	-	-	-
(ii) (a) Items that will be reclassified to profit & loss	-	-	-	-	-
(b) Tax expense/(benefit) on items that will be reclassified to profit or loss	-	-	-	-	-
Total Other comprehensive (loss)/ income (net of tax)	0.31	0.50	(6.73)	2.49	(6.60)
9. Total comprehensive income for the period	(232.21)	258.48	(307.52)	187.82	94.57
10. Paid-up equity share capital (Face Value Rs. 10 Each)	2,104.06	2,104.06	2,104.06	2,104.06	2,104.06
11. Other equity (excluding revaluation reserve)				7,933.20	7,745.37
12. Debenture Redemption Reserve					
13. Basic and Diluted Earnings per share after extraordinary items (not annualized)	(1.10)	1.23	(1.46)	0.89	0.45

Notes -

- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, read with rule 3 of the Companies (Indian accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Accounting Rules, 2016
- The Company is operating in the single segment of Drugs & Chemicals.
- The Figures of Previous Year/ Periods may have been regrouped/reclassified/restated wherever necessary.
- Stock Market had crashed in the month of March, 2020. As a result, NAV's of mutual funds had also fallen sharply as on the Balance sheet date resulting in significant loss of fair value of mutual funds amounting to 271.03 lakhs for the quarter ending 31st March, 2020 and 248.87 lakhs for the year ending 31st March, 2020.

For Alpa Laboratories Ltd.

Mahendra
Mahendra Singh Chauhan
Director
DIN-00362058



**INDEPENDENT AUDITORS REPORT ON AUDIT OF ANNUAL CONSOLIDATED
FINANCIAL RESULTS AND REVIEW OF THE QUARTERLY FINANCIAL RESULTS.**

TO THE BOARD OF DIRECTORS OF

ALPA LABORATORIES LIMITED

OPINION

I have (a) audited the consolidated financial statements of the year ended 31st March, 2020 and (b) reviewed the consolidated financial results for the quarter ended 31st March 2020 which were subject to limited review by us both included in the accompanying "Statement of Financial results for the quarter and year ended 31st March 2020 of **ALPA LABORATORIES LIMITED, being submitted by the company pursuant to the requirements of regulation 33 of the SEBI LODR, 2015 as amended**

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the audit reports of the other auditors on separate financial statements of associate and joint venture referred to in other matters section below, the consolidation financial results for the year ended 31st March, 2020:

a. includes the results of the following entities:

Wholly Owned Subsidiary:


1. Norfolk Mercantile Private Limited

b. are presented in accordance with the requirements of the regulation 33 of the Listing Regulation in this regard.

c. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian accounting standards and other accounting principle generally accepted in India of the net profit and other comprehensive income and other financial information for the year ended 31st March, 2020

Basis for opinion

I conducted our audit in accordance with the Standards on Auditing (SAs) specified U/s. 143(10) of the Companies Act, 2013 ("The Act"). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled





our other ethical responsibilities in accordance with these requirements and the Code of Ethics. / We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the financial statements.

Management and Board of Directors Responsibilities for the consolidated audited financial results


The Company's Management and the Board of Directors are responsible for the preparation and presentation of these consolidated financial statements that give a true and fair view of the of the net profit and other comprehensive income and other financial information in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified u/s 133 of the Act and other accounting principles generally accepted in India and in compliance with regulation 33 of the listing regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the company's financial reporting process.

Auditor's Responsibility for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could






reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. U/s.143(3)(i) of the 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with



Anuradha Ratnaparkhi & Associates

CHARTERED ACCOUNTANTS

Anuradha Ratnaparkhi

M.com., FCA



9D, Sampat Farms, Survey No. 15/26,
Opp. Agrawal Public School,
Bicholi Mardana Road, Indore 452 016 (M.P.)
Tel. : +91 731-4979244, M : +91 98934-62644
E-mail : associate@caanuradha.co.in

them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

OTHER MATTERS.

The statement includes the results for the quarter ended 31st March 2020 being the balancing figure between audited figures in respect of the full financial year and the published year ton date figure upto the third quarter of the current financial year which were subject to limited review by us.

For Anuradha Ratnaparkhi & Associates.

Chartered Accountants

Firm Registration No.023451C

Anuradha Ratnaparkhi

Proprietor

Membership Number:075412

UDIN- 20075412AAAAAD8259



Place: Indore

Date: June 29,2020

ALPA LABORATORIES LIMITED

Financial Results for Quarter and Financial Year ended 31st March 2020

33/2 PIGDAMBER, A.B. ROAD, RAU
INDORE (M.P.) 453446
(Rs. in lacs except EPS)

Particulars	Standalone		Consolidated	
	Mar-20	Mar-19	Mar-20	Mar-19
	Audited	Audited	Audited	Audited
IV. Statement of Cash Flows - Standalone and Consolidated				
CASH FLOW FROM OPERATING ACTIVITIES:				
Profit / (loss) before tax	507.73	462.23	290.75	275.63
Adjustments for:				
Depreciation and amortization	114.20	109.57	316.45	311.82
Finance cost	19.94	56.87	19.62	56.87
Dividend income	(108.61)	(95.22)	(108.61)	(95.22)
Interest income	(42.21)	(261.95)	(55.38)	(290.55)
Net (Gain)/Loss on sale / fair valuation of investments through profit and loss	208.76	(46.03)	227.37	(40.79)
Bad debts / assets written off	175.34	125.60	184.47	132.97
Share of Loss/(Profit) from Investment in LLP	(3.00)	4.09	(3.00)	4.09
(Profit)/ loss on sale of Fixed Assets (net)	5.28	-	5.28	-
Operating profit before working capital changes	877.43	355.16	876.94	354.83
Changes in Operating assets and liabilities:				
Decrease/ (Increase) in Trade Receivable/Other Receivables	959.80	(759.48)	977.65	(723.73)
Decrease/ (Increase) in Inventories	148.82	(31.56)	148.82	(31.56)
Increase/ (Decrease) in Provisions	8.44	327.18	8.54	327.06
Increase/ (Decrease) in Trade payable/Current Liabilities	(118.40)	250.35	(119.85)	189.50
Net Cash Flow from Operating Activities	1,876.08	141.64	1,892.09	116.10
Income taxes paid	(110.40)	(209.45)	(115.89)	(216.60)
Net Cash Flow from Operating Activities Before Exceptional Items	1,765.68	(67.81)	1,776.20	(100.51)
Exceptional Items	-	-	-	-
Net Cash Flow from Operating Activities After Exceptional Items (I)	1,765.68	(67.81)	1,776.20	(100.51)
CASH FLOW FROM INVESTING ACTIVITIES:				
Proceeds from/(Payments for):				
Dividend received from others	108.61	95.22	108.61	95.22
Interest Received	42.21	261.95	55.38	290.55
Property, plant and equipment	(254.53)	(85.31)	(254.53)	(85.31)
Purchase of investment	(1,160.84)	(1,187.16)	(1,160.84)	(1,187.16)
Investment in subsidiaries/ Joint Venture	137.16	(579.34)	137.16	(579.34)
Net Cash Flow from Investing Activities (II)	(1,127.39)	(1,494.64)	(1,114.22)	(1,466.04)
CASH FLOW FROM FINANCING ACTIVITIES:				
Proceeds from/(Payments for):				
Long Term Borrowings	(21.93)	(20.24)	(21.93)	(20.24)
Short Term Borrowings	(105.31)	(412.41)	(105.31)	(412.41)
Interest Paid	(19.94)	(56.87)	(19.62)	(56.87)
Government Grant received	11.94	11.94	11.94	11.94
Net Cash Flow from Financing Activities (III)	(135.24)	(477.57)	(134.92)	(477.57)
Net Increase/(Decrease) In Cash and Cash Equivalents (I + II + III)	503.05	(2,040.02)	527.06	(2,044.12)
Cash and Cash Equivalents as at the beginning of the year	88.48	2,128.50	89.91	2,134.03
Cash and Cash Equivalents as at the end of the year	591.53	88.48	616.97	89.91
Cash and Cash Equivalents Comprise of:				
Cash and Bank Balances	472.03	13.48	497.47	14.91
Fixed Deposits with Banks	119.50	75.00	119.50	75.00
Total Cash & Cash Equivalents	591.53	88.48	616.97	89.91

For Alpa Laboratories Ltd.

Mahendra
Mahendra Singh Chawla
Director
DIN-00362058

ALPA LABORATORIES LIMITED

Financial Results for Quarter and Financial Year ended 31st March 2020

33/2 PIGDAMBER, A.B. ROAD, RAU
INDORE (M.P.) 453446
(Rs. in lacs except EPS)

Particulars	Standalone		Consolidated	
	Mar-20	Mar-19	Mar-20	Mar-19
	Audited	Audited	Audited	Audited
III. Statement of Assets and Liabilities				
ASSETS				
<i>Non-current Assets</i>				
(a) Property, plant and equipment	641.64	576.08	641.64	576.08
(b) Capital work-in-progress	81.27	11.78	81.27	11.78
(c) Goodwill	-	-	-	202.25
(d) Investments in subsidiaries, associates and joint venture	1102.45	1083.85	-	-
(e) Financial assets				
(i) Investments	1728.71	1862.87	1,728.71	1,862.87
(ii) Other Financial Assets	44.63	43.02	44.63	43.02
(f) Deferred tax assets (Net)	92.58	17.10	92.58	17.10
<i>Current Assets</i>				
(a) Inventories	1255.05	1403.87	1,255.05	1,403.87
(b) Financial Assets				
(i) Investments	3929.58	2996.10	3,929.58	2,996.10
(ii) Trade Receivables	2458.96	2980.94	2,458.96	2,999.80
(iii) Cash and cash equivalents	472.03	13.48	497.47	14.91
(iv) Bank Balances other than cash and cash equivalents	119.50	75.00	119.50	75.00
(v) Loans	29.69	503.50	98.87	594.61
(vi) Other financial assets	237.02	328.69	237.02	312.25
(c) Current Tax Assets (net)	-	32.00	-	32.00
(d) Other current assets	927.17	953.91	949.83	979.20
TOTAL - ASSETS	13120.29	12,882.19	12,135.12	12,120.85
EQUITY AND LIABILITIES				
<i>Equity</i>				
(a) Equity Share Capital	2,104.06	2,104.06	2,104.06	2,104.06
(b) Other Equity	8,918.90	8,508.60	7,933.20	7,745.37
<i>Liabilities</i>				
<i>Non-current liabilities</i>				
(a) Financial Liabilities				
(i) Borrowings	19.20	41.13	19.20	41.13
<i>Current liabilities</i>				
(a) Financial Liabilities				
(i) Borrowings	-	105.31	-	105.31
(ii) Trade payables	1,371.68	1,318.46	1,372.32	1,318.88
(iii) Other financial liabilities	150.39	148.41	150.09	148.41
(b) Short term provisions	232.25	223.81	232.47	223.93
(c) Current tax Liabilities (Net)	65.00	-	65.00	-
(d) Other current liabilities	258.82	432.40	258.79	433.75
TOTAL - EQUITY AND LIABILITIES	13120.29	12,882.19	12,135.12	12,120.85

For Alpa Laboratories Ltd.

Mahendra Singh Chawla
Mahendra Singh Chawla
Director
DIN-00362058